SCHEMBL7083553

SCHEMBL7083553

O=C(O)c1c(Cl)c2cc(O)ccc2n1Cc1ccc(C(F)(F)F)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 4/20 0.51
CCR2 P41597 8/20 0.49
PTGER4 P35408 1/20 0.41
S1PR3 Q99500 2/20 0.40
MAPT P10636 3/20 0.40
PKM P14618 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PPARG P37231 2/20 0.40
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
P2RX7 Q99572 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7082969 0.87 ABCB11 (0.46) ABCB11CCR2PTGER4S1PR3MAPT
SCHEMBL6599182 0.81 ABCB11 (0.73) ABCB11CCR2
SCHEMBL7086963 0.80 ABCB11 (0.55) ABCB11CCR2MAPTPKMKDM4E
SCHEMBL7089675 0.79 ABCB11 (0.48) ABCB11CCR2S1PR3MAPTPKM
SCHEMBL7084277 0.78 ABCB11 (0.63) ABCB11CCR2
SCHEMBL7088120 0.77 ABCB11 (0.74) ABCB11CCR2PPARG
SCHEMBL7083775 0.76 ABCB11 (0.78) ABCB11CCR2MAPTPKMKDM4E
SCHEMBL7089748 0.73 GAA (0.41) ABCB11MAPTPKMKDM4EPPARG
SCHEMBL7089579 0.73 MAPT (0.57) CCR2MAPTKDM4EPPARGMEN1
SCHEMBL6307041 0.73 CCR2 (0.72) ABCB11CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030144339-A1 Indole derivatives as mcp-1 receptor antagonists ASTRAZENECA AB (SE) 2003-07-31 US claimed
CN-1395565-A Indole derivatives as MCP-1 receptor antagonists ASTRAZENECA AB (SE) 2003-02-05 CN claimed
EP-1252142-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2002-10-30 EP claimed
WO-2001051466-A1 INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2001-07-19 WO claimed
US-20030144339-A1 Indole derivatives as mcp-1 receptor antagonists ASTRAZENECA AB (SE) 2003-07-31 US disclosed
CN-1395565-A Indole derivatives as MCP-1 receptor antagonists ASTRAZENECA AB (SE) 2003-02-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144339-A1 Indole derivatives as mcp-1 receptor antagonists CCR2, CCR1, CCR5 ABCB11 391/4885CCR2 1/4885PTGER4 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.